Choroidal neovascularization secondary to cuticular drusen treated with intravitreal bevacizumab.
OBJECTIVE
To report our experience with intravitreal injection of bevacizumab in the treatment of cuticular drusen-associated choroidal neovascularization.


METHODS
An interventional case report. A 38-year-old woman presented with decreased visual acuity in her right eye and cuticular drusen-associated choroidal neovascularization.


RESULTS
Prolonged (12 months) remission of choroidal neovascularization after 3 monthly bevacizumab injections with improvement in visual acuity from 20/120 to 20/20.


CONCLUSIONS
The use of antivascular endothelial growth factor in the management of cuticular drusen-associated choroidal neovascularization seems to be an effective method of treatment showing both resolution of optical coherence tomography changes and improvement in visual acuity in this case. However, further studies with bigger sample size and longer follow-up are required to confirm the findings.
*VMO, Centre for Excellence in Indigenous Health, Brisbane, Australia; and †Porter Eye Care, Brisbane, Australia.
Rowan G B
RG
Porter
Samyukta B
SB
Karki
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D015593:Retinal Drusen / Q000150:complications*; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab